Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.9K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

582
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.6K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

839
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
839
Angina IV: Management01:26

Angina IV: Management

419
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
419

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple Antibiotic Allergy Evaluation Strategy (MAAES): A Comparative Effectiveness Study.

The journal of allergy and clinical immunology. In practice·2026
Same author

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

Prospective longitudinal study of psychological sequelae, self-perception of body image, and quality of life in severe cutaneous adverse drug reactions: a case-control study.

Frontiers in medicine·2026
Same author

Comprehensive mapping of human CD4<sup>+</sup> T cell epitopes for Nipah and measles as prototype Paramyxoviruses.

Cell reports. Medicine·2026
Same author

Isotopic Fractionation and Masking Effects during Biotransformation of Chlorinated Ethanes.

Environmental science & technology·2026
Same author

The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia-Best evidence and practices aligned.

Journal of clinical lipidology·2026

Related Experiment Video

Updated: Mar 29, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.9K

Current Controversies With Recent Cholesterol Treatment Guidelines.

Elizabeth Phillips1, Joseph J Saseen2

  • 1Department of Pharmacy Practice, Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY, USA Department of Medicine, Section of Clinical Pharmacology, SUNY-Upstate Medical University, Aurora, CO, USA.

Journal of Pharmacy Practice
|November 28, 2015
PubMed
Summary

Recent guidelines offer different approaches to managing atherosclerotic cardiovascular disease (ASCVD) risk, focusing on statin therapy intensity versus patient-specific lipid targets. Understanding these controversies is key for effective ASCVD risk reduction and patient care.

Keywords:
ASCVDatherosclerotic cardiovascular disease riskcholesterolcontroversydyslipidemiaguidelinesstatins

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

Related Experiment Videos

Last Updated: Mar 29, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Background:

  • Recent guidelines address atherosclerotic cardiovascular disease (ASCVD) risk management.
  • Divergent recommendations exist for cholesterol treatment strategies.

Purpose of the Study:

  • To review and compare current guidelines for ASCVD risk management.
  • To highlight controversies in statin and non-statin therapy for ASCVD risk reduction.

Main Methods:

  • Comparative analysis of recent expert recommendations and guidelines.
  • Review of therapeutic approaches for cholesterol management.
  • Discussion of controversies in ASCVD risk treatment.

Main Results:

  • ACC/AHA guidelines advocate fixed-intensity statin therapy based on risk.
  • National Lipid Association (NLA) recommendations support titrating therapy to lipid targets.
  • Statin therapy is consistently emphasized for cardiovascular event risk reduction.

Conclusions:

  • Clinicians must be aware of differing guideline approaches to ASCVD risk.
  • Controversies include the role of non-statin drugs and side effect management.
  • Implications for patient care necessitate understanding these treatment variations.